SCHEMBL4296572

SCHEMBL4296572

CNS(=O)(=O)N(C)c1ccc2ccc3ncc(-c4cnn(CC(=O)N5CCOCC5)c4)cc3c(=O)c2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.76
MST1R Q04912 2/20 0.47
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
ABL1 P00519 1/20 0.47
NTRK1 P04629 1/20 0.47
RET P07949 1/20 0.47
CYP3A4 P08684 1/20 0.47
PDGFRB P09619 1/20 0.47
FGFR1 P11362 1/20 0.47
CYP2C9 P11712 1/20 0.47
NQO2 P16083 1/20 0.47
FLT1 P17948 1/20 0.47
FGFR2 P21802 1/20 0.47
FGFR3 P22607 1/20 0.47
FECH P22830 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
FLT3 P36888 1/20 0.47
MAPK9 P45984 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2444440 0.87 MET (1.00) METMST1RAURKAJAK2ABL1
SCHEMBL2326458 0.84 MET (0.84) METMST1R
SCHEMBL2448744 0.82 MET (0.72) METMST1R
SCHEMBL2322770 0.81 MET (0.72) METMST1R
SCHEMBL2446196 0.74 MET (0.76) METMST1R
SCHEMBL399862 0.73 MET (0.70) METMST1RCYP3A4CYP2C9FECH
SCHEMBL2447031 0.73 MET (0.67) METMST1RAURKAJAK2ABL1
SCHEMBL2449387 0.73 MET (0.63) METMST1RAURKAJAK2ABL1
SCHEMBL2452747 0.73 MET (0.69) METMST1R
SCHEMBL3952870 0.72 MET (0.69) METMST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207186-B2 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET MERCK SHARP & DOHME CORP. (US) 2012-06-26 US disclosed
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MERCK SHARP & DOHME LLC 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MET, RET, ERBB2 MET 1/4885MST1R 62/4885AURKA 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.